×
S&P 500   3,766.10 (-0.51%)
DOW   30,598.30 (-0.58%)
QQQ   279.21 (-0.38%)
AAPL   136.74 (+0.01%)
MSFT   256.79 (-0.02%)
META   156.66 (-2.85%)
GOOGL   2,151.25 (-1.29%)
AMZN   108.17 (+1.85%)
TSLA   676.17 (+0.41%)
NVDA   146.34 (-3.46%)
NIO   21.29 (-1.98%)
BABA   115.07 (+1.22%)
AMD   73.49 (-3.90%)
MU   52.19 (-5.59%)
CGC   2.79 (-2.11%)
T   21.06 (+0.48%)
GE   62.67 (-1.57%)
F   11.15 (+0.18%)
DIS   94.88 (+0.51%)
AMC   13.56 (+0.07%)
PFE   51.77 (-1.26%)
PYPL   70.22 (+0.54%)
NFLX   177.10 (+1.28%)
S&P 500   3,766.10 (-0.51%)
DOW   30,598.30 (-0.58%)
QQQ   279.21 (-0.38%)
AAPL   136.74 (+0.01%)
MSFT   256.79 (-0.02%)
META   156.66 (-2.85%)
GOOGL   2,151.25 (-1.29%)
AMZN   108.17 (+1.85%)
TSLA   676.17 (+0.41%)
NVDA   146.34 (-3.46%)
NIO   21.29 (-1.98%)
BABA   115.07 (+1.22%)
AMD   73.49 (-3.90%)
MU   52.19 (-5.59%)
CGC   2.79 (-2.11%)
T   21.06 (+0.48%)
GE   62.67 (-1.57%)
F   11.15 (+0.18%)
DIS   94.88 (+0.51%)
AMC   13.56 (+0.07%)
PFE   51.77 (-1.26%)
PYPL   70.22 (+0.54%)
NFLX   177.10 (+1.28%)
S&P 500   3,766.10 (-0.51%)
DOW   30,598.30 (-0.58%)
QQQ   279.21 (-0.38%)
AAPL   136.74 (+0.01%)
MSFT   256.79 (-0.02%)
META   156.66 (-2.85%)
GOOGL   2,151.25 (-1.29%)
AMZN   108.17 (+1.85%)
TSLA   676.17 (+0.41%)
NVDA   146.34 (-3.46%)
NIO   21.29 (-1.98%)
BABA   115.07 (+1.22%)
AMD   73.49 (-3.90%)
MU   52.19 (-5.59%)
CGC   2.79 (-2.11%)
T   21.06 (+0.48%)
GE   62.67 (-1.57%)
F   11.15 (+0.18%)
DIS   94.88 (+0.51%)
AMC   13.56 (+0.07%)
PFE   51.77 (-1.26%)
PYPL   70.22 (+0.54%)
NFLX   177.10 (+1.28%)
S&P 500   3,766.10 (-0.51%)
DOW   30,598.30 (-0.58%)
QQQ   279.21 (-0.38%)
AAPL   136.74 (+0.01%)
MSFT   256.79 (-0.02%)
META   156.66 (-2.85%)
GOOGL   2,151.25 (-1.29%)
AMZN   108.17 (+1.85%)
TSLA   676.17 (+0.41%)
NVDA   146.34 (-3.46%)
NIO   21.29 (-1.98%)
BABA   115.07 (+1.22%)
AMD   73.49 (-3.90%)
MU   52.19 (-5.59%)
CGC   2.79 (-2.11%)
T   21.06 (+0.48%)
GE   62.67 (-1.57%)
F   11.15 (+0.18%)
DIS   94.88 (+0.51%)
AMC   13.56 (+0.07%)
PFE   51.77 (-1.26%)
PYPL   70.22 (+0.54%)
NFLX   177.10 (+1.28%)
NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$10.78
+0.04 (+0.37%)
(As of 07/1/2022 11:46 AM ET)
Add
Compare
Today's Range
$10.65
$10.96
50-Day Range
$6.23
$11.12
52-Week Range
$5.91
$12.63
Volume
151,099 shs
Average Volume
3.55 million shs
Market Capitalization
$3.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock Forecast (MarketRank)

Overall MarketRank

1.94 out of 5 stars

Medical Sector

662nd out of 1,429 stocks

Pharmaceutical Preparations Industry

312th out of 682 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
Amicus Therapeutics logo

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Company Calendar

Last Earnings
5/09/2022
Today
7/01/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+39.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.625
Research Coverage
8 Analysts

Profitability

Net Income
$-250.46 million
Pretax Margin
-81.47%

Debt

Sales & Book Value

Annual Sales
$305.51 million
Book Value
$1.10 per share

Miscellaneous

Free Float
274,280,000
Market Cap
$3.02 billion
Optionable
Optionable
Beta
1.41

Social Links















Amicus Therapeutics Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2022?

8 equities research analysts have issued 1 year price targets for Amicus Therapeutics' shares. Their FOLD stock forecasts range from $14.00 to $16.00. On average, they predict Amicus Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 38.4% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Amicus Therapeutics' stock performed in 2022?

Amicus Therapeutics' stock was trading at $11.55 at the beginning of the year. Since then, FOLD shares have decreased by 6.1% and is now trading at $10.84.
View the best growth stocks for 2022 here
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.06. The biopharmaceutical company had revenue of $78.72 million for the quarter, compared to analyst estimates of $76.97 million. Amicus Therapeutics had a negative net margin of 84.97% and a negative trailing twelve-month return on equity of 95.05%. During the same period last year, the company posted ($0.25) EPS.
View Amicus Therapeutics' earnings history
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350.00 million-$365.00 million, compared to the consensus revenue estimate of $363.85 million.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 55, Pay $2.06M) (LinkedIn Profile)
  • Mr. Bradley L. Campbell M.B.A., Pres, COO & Director (Age 46, Pay $947.8k) (LinkedIn Profile)
  • Ms. Daphne E. Quimi CPA, Chief Financial Officer (Age 56, Pay $785.38k)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 59, Pay $771.52k)
  • Mr. David M. Clark, Chief People Officer (Age 47, Pay $738.22k)
  • Ms. Samantha Prout, VP, Global Controller & Principal Accounting Officer (Age 44) (LinkedIn Profile)
  • Andrew Faughnan, Sr. Director of Investor Relations
  • Mr. Patrik S. Florencio, Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore, Head of Global Corp. Communications
  • Ms. Jayne C. Gershkowitz, Chief Patient Advocate (Age 65)

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $10.84.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.04 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250.46 million in net income (profit) each year or ($0.970010) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 496 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for Amicus Therapeutics is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at [email protected], or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.